$BG

Mahoney Christopher purchased $689K of BG

Mahoney Christopher purchased 6,500 shares of Bunge Global SA (BG) at an average of $106.01 ($105.53–$107.60, $0.69M total) across 2 trades over 2026-07-31 to 2026-08-04.

Original reporting
SEC EDGAR · Mahoney Christopher
Published Aug 4, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 6:22 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$BG
Bullish
low confidence
Mentioned
$BG
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BGBullishLow
01

Why it matters

A director open-market purchase of 6,500 shares is newly disclosed, but it does not include any new guidance, contract, or regulatory development.

02

Market read

Traders may note the insider buy as a small sentiment input, but it is unlikely to materially change valuation without other catalysts.

03

What to watch

The article does not state intent, option exercises, or whether the director’s prior holdings were already large; without context, the buy size may be less informative.

Relevance 6/10Novelty 3/10Timing: filed 2026-08-04, covers buys from 2026-07-31 to 2026-08-04

Background

The article is an SEC Form 4 insider transaction disclosure for Bunge Global SA (BG).

Company-level read

Ticker impact

$BGBullishLow confidence
Context

Bunge Global SA director Christopher Mahoney bought 6,500 shares in open-market trades for about $689,050, per a fresh Form 4 filed Aug 4.

Expected impact

Likely limited near-term price impact; any effect is sentiment-driven and small versus earnings or guidance.

Evidence & confidence

The filing is a routine insider transaction with no 10b5-1 plan and no accompanying company-specific operational or financial disclosure.

Market effects

No direct sector read-through; insider buys are company-specific and typically do not reset sector expectations.

None indicated.

None indicated.

Counterpoint

Insider buys can be driven by diversification, liquidity needs, or pre-planned behavior, so the signal may be weak.

Key entities

  • Bunge Global SA

    Subject of the Form 4 insider transaction disclosure.

  • Christopher Mahoney

    Director who purchased shares in open-market trades.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BGMed

Why Bunge Global (BG) Stock Is Up Today

Bunge Global (BG) shares rose 2.8% after announcing the sale of two Brazilian sugarcane mills to COFCO International. The deal aims to optimize Bunge's asset base and focus on core supply chain activities. BG is up 28.9% YTD but trades 9.1% below its 52-week high. The stock has low volatility, with only 5 moves over 5% in the past year.

$DARMedAI 8/10

A Look Back at Ingredients, Flavors & Fragrances Stocks’ Q2 Earnings: Darling Ingredients (NYSE:DAR) Vs The Rest Of The Pack

Ingredients, flavors, and fragrances stocks reported mixed Q2 earnings, with revenues missing estimates by 2.4%. Darling Ingredients (DAR) reported $1.72B revenue, up 16.4% YoY, beating estimates. Archer-Daniels-Midland (ADM) reported $22.68B revenue, up 7.2% YoY, outperforming estimates. International Flavors & Fragrances (IFF) reported $1.95B revenue, down 29.3% YoY, missing estimates. Ingredion (INGR) reported $1.85B revenue, flat YoY, topping estimates. Bunge Global (BG) reported $24.04B rev

$BGMed

Why is Bunge stock rallying today?

Investing.com reports Bunge shares rose about 3.7% after its Q2 2026 results (released July 29). Adjusted EPS was $2.00 vs ~$1.95 expected, and revenue was $24.04B vs expectations. The stock had fallen on concerns about Viterra integration and working capital. Analysts at Texas Capital and BMO reiterated Buy, with a $150 target, and an Aug. 18 ex-dividend date for a $0.72 quarterly payment.

$BGMedAI 8/10

PTSB acquisition: Shareholders approve transaction

Permanent TSB (PTSB) shareholders approved BAWAG Group’s all-cash offer to buy 100% of PTSB’s issued share capital. The scheme meeting vote backed the transaction with 91% of votes cast, and related resolutions at the EGM received required approvals. Completion is expected in Q4 2026 or Q1 2027, pending court sanction and remaining regulatory approvals.

$BGMedAI 8/10

Bunge Global Raises 2026 Adj. EPS Outlook Range

Bunge Global SA (BG) raised its 2026 adjusted EPS outlook to $9.25 to $9.75 from $9.00 to $9.50, citing higher Soybean Processing and Refining and Softseed Processing and Refining, and lower Grain Merchandising and Milling. Q2 earnings were $678 million, or $3.47/share, versus $354 million, or $2.61/share a year earlier. Revenue rose 88.3% to $24.041 billion. Shares were up 1.29% pre-market at $118.88.

$BGMed

Bunge Global (NYSE:BG) Beats Q2 CY2026 Sales Expectations

Bunge Global (NYSE:BG) reported Q2 CY2026 results, with sales rising 88.3% year on year to $24.04 billion, topping Wall Street’s revenue estimate by 9.3%, according to the company. Non-GAAP profit was $2 per share, 2.9% above consensus. The article also cites Q2 cash burn of $1.03 billion and notes the stock was about $117.50 after results.